Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.14978 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Akihiko Koshino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fatty Liver, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Janssen Research and Development, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science KAKENHI.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan The George Institute for Global Health, UNSW, Sydney, Australia Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia Department of Medicine, AHA Comprehensive Hypertension Center University of Chicago Medicine, Chicago, Illinois, USA NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia Concord Repatriation General Hospital, Sydney, Australia Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California, USA University of New South Wales, Sydney, Australia Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, Australia Royal North Shore Hospital, St Leonards, Australia
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.
- The George Institute for Global Health, UNSW, Sydney, Australia.
- Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.
- Department of Medicine, AHA Comprehensive Hypertension Center University of Chicago Medicine, Chicago, Illinois, USA.
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
ORCID-Profile: Akihiko Koshino, Clare Arnott, George L Bakris, Hiddo J L Heerspink, Brendon L Neuen
Förderung
- Janssen Research and Development
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science KAKENHI
Zitieren
APA
Koshino, A., Oshima, M., Arnott, C., Fletcher, R. A., Bakris, G. L., Jardine, M., Mahaffey, K. W., Perkovic, V., Pollock, C., Heerspink, H. J. L., & Neuen, B. L. (2023). Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14978
Vancouver
Koshino A, Oshima M, Arnott C, Fletcher RA, Bakris GL, Jardine M, et al. Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.14978
BibTeX
@article{Koshino2023,
author = {Koshino, Akihiko and Oshima, Megumi and Arnott, Clare and Fletcher, Robert A and Bakris, George L and Jardine, Meg and Mahaffey, Kenneth W and Perkovic, Vlado and Pollock, Carol and Heerspink, Hiddo J L and Neuen, Brendon L},
title = {Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.14978}
}
EUVIMED